AZN - Spark Newswire

2 minute read

$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns

Today, 10:32 PM

The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths.

AZN

1 minute read

News

Fiancial Times Reported Sunday AstraZeneca Entered $157M Licensing Deal With RQ Bio For Experimental Covid-19 Therapies

By Charles Gross

Today, 10:32 PM

https://www.ft.com/content/af9174df-2d5d-4452-ba91-bf1ab1714f1a

AZN

1 minute read

U.S. Fda Announces Evusheld Is Not Currently Authorized For Emergency Use In U.S.; FDA Data Shows Evusheld Is Unlikely To Be Active Against Certain Sars-Cov-2 Variants

By Benzinga Newsdesk

Today, 10:32 PM

- Reuters

AZN

3 minute read

AstraZeneca Announced Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer

By Charles Gross

Today, 10:32 PM

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

AZN

1 minute read

AstraZeneca Announced Tezspire Approved For Self-administration In The EU In A New Pre-filled Pen

By Charles Gross

Today, 10:32 PM

AstraZeneca's Tezspire (tezepelumab) has received a positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

AZN

1 minute read

FDA
News

Airsupra (PT027) Approved In U.S. For asthma

By Benzinga Newsdesk

Today, 10:32 PM

https://news.cision.com/se/astrazeneca/r/airsupra--pt027--approved-in-the-us-for-asthma%2Cc3696063

AZN

2 minute read

What Does AstraZeneca’s Debt Look Like?

By Benzinga Insights

Today, 10:32 PM

Shares of AstraZeneca Inc. (NASDAQ:AZN) moved higher by 28.78% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.

AZN

1 minute read

Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study

By Vandana Singh

Today, 10:32 PM

Valneva SE (NASDAQ:VALN) reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001. The…

AZN

1 minute read

News

Drugmakers To Raise Prices On At Least 350 Drugs In U.S. In January

By Benzinga Newsdesk

Today, 10:32 PM

Drugmakers including Pfizer Inc PFE.N, GlaxoSmithKline PLC GSK.L, Bristol Myers Squibb BMY.N, AstraZeneca PLC AZN.L and Sanofi SA SASY.PA plan to raise prices in the United States on

AZN

3 minute read

FDA
News

AstraZeneca Announced Calquence Approved in Japan for Adults with Treatment Naïve Chronic Lymphocytic Leukaemia

By Charles Gross

Today, 10:32 PM

AstraZeneca's Calquence (acalabrutinib), a selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). Calquence was previously approved in Japan for the treatment of adults with relapsed or refractory CLL.

AZN

Feed Symbols: AZN